The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-05-18
DOI
10.1038/s41598-017-02634-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA
- (2016) Christine Katlama et al. AIDS
- Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy
- (2016) Carolina Gutiérrez et al. AIDS
- IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle
- (2016) Mayte Coiras et al. Cell Reports
- A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes
- (2016) R. Brad Jones et al. PLoS Pathogens
- Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal
- (2015) Marta Martínez-Bonet et al. ANTIVIRAL RESEARCH
- Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations
- (2015) Gregory M. Laird et al. JOURNAL OF CLINICAL INVESTIGATION
- Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies
- (2015) Amanda M. Crooks et al. JOURNAL OF INFECTIOUS DISEASES
- A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity
- (2015) Javier Garcia-Perez et al. Retrovirology
- Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1
- (2015) Marta Martínez-Bonet et al. Scientific Reports
- An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression
- (2015) Gilles Darcis et al. PLoS Pathogens
- Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction
- (2015) Mario Ostrowski et al. Open Forum Infectious Diseases
- Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression
- (2014) Nadejda Beliakova-Bethell et al. ANTIVIRAL RESEARCH
- In Vitro Immunological Effects of Blocking CCR5 on T Cells
- (2014) Jing Yuan et al. INFLAMMATION
- An In Vitro System to Model the Establishment and Reactivation of HIV-1 Latency
- (2014) A. Marini et al. JOURNAL OF IMMUNOLOGY
- HIV-1 persistence in CD4+ T cells with stem cell–like properties
- (2014) Maria J Buzon et al. NATURE MEDICINE
- New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo
- (2014) C Korin Bullen et al. NATURE MEDICINE
- A primary CD4+ T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence
- (2014) Michelle Kim et al. Nature Protocols
- Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy
- (2014) A. R. Cillo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
- (2014) Datsen George Wei et al. PLoS Pathogens
- Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial
- (2014) Alain Lafeuillade et al. AIDS Research and Therapy
- Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection
- (2013) Maria C. Puertas et al. AIDS
- Pharmacokinetics, Safety, and Tolerability of Maraviroc in HIV-Negative Subjects with Impaired Renal Function
- (2013) Manoli Vourvahis et al. HIV CLINICAL TRIALS
- Combined approaches for HIV cure
- (2013) David M. Margolis et al. Current Opinion in HIV and AIDS
- Comparison of HDAC inhibitors in clinical development
- (2013) Thomas Aagaard Rasmussen et al. Human Vaccines & Immunotherapeutics
- 24 Hours in the Life of HIV-1 in a T Cell Line
- (2013) Pejman Mohammadi et al. PLoS Pathogens
- An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients
- (2013) Celsa A. Spina et al. PLoS Pathogens
- Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies
- (2013) Susanne Eriksson et al. PLoS Pathogens
- Maraviroc Intensification of Stable Antiviral Therapy in HIV-1–Infected Patients With Poor Immune Restoration
- (2012) Lise Cuzin et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- In vitro effects of the CCR5 inhibitor maraviroc on human T cell function
- (2012) H. Arberas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Shock and kill
- (2012) Steven G. Deeks NATURE
- Protein Kinase Cθ Is a Specific Target for Inhibition of the HIV Type 1 Replication in CD4+T Lymphocytes
- (2011) María Rosa López-Huertas et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5)
- (2011) Javier Garcia-Perez et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity
- (2011) Ildefonso Pulido et al. JOURNAL OF INFECTION
- Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected
- (2011) Carolina Gutiérrez et al. PLoS One
- Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells
- (2011) Suha Saleh et al. Retrovirology
- Homeostatic Proliferation Fails to Efficiently Reactivate HIV-1 Latently Infected Central Memory CD4+ T Cells
- (2011) Alberto Bosque et al. PLoS Pathogens
- Maternal-Fetal Pharmacokinetics and Dynamics of a Single Intrapartum Dose of Maraviroc in Rhesus Macaques
- (2010) M. A. Winters et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency
- (2010) Moises Perez et al. CURRENT HIV RESEARCH
- New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection
- (2010) Javier Garcia-Perez et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells
- (2010) Alberto Bosque et al. METHODS
- Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner
- (2010) Rajeev Mehla et al. PLoS One
- Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients
- (2010) Nicholas Funderburg et al. PLoS One
- Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton
- (2010) P. U. Cameron et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection
- (2009) I. Sereti et al. BLOOD
- HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
- (2009) Nicolas Chomont et al. NATURE MEDICINE
- Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs
- (2009) Mayte Coiras et al. NATURE REVIEWS MICROBIOLOGY
- The Challenge of Finding a Cure for HIV Infection
- (2009) D. D. Richman et al. SCIENCE
- Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects
- (2008) Samantha Abel et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
- (2008) B. F. Keele et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now